Treatment of Philadelphia1 leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides

Journal of the National Cancer Institute

Volumn 89, Issue 2, 1997, Pages 124-133

  Skorski, Tomasz ^a   Nieborowska Skorska, M ^a   Wlodarski, P ^a   Perrotti, D ^b   Hoser, G ^c   Kawiak, J ^c   Majewski, M ^b   Christensen, L ^d   Iozzo, R V ^b   Calabretta, Bruno ^b,e  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^d ILLUMINA INC   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; MAFOSFAMIDE; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; DRUG DERIVATIVE; NUCLEOTIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; COMBINED IMMUNODEFICIENCY; DRUG EFFICACY; GENE TARGETING; LEUKEMIA CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PHILADELPHIA 1 CHROMOSOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY; ANIMAL; BIOSYNTHESIS; BONE MARROW; BONE MARROW CELL; CELL CULTURE; DNA PROBE; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; POLYMERASE CHAIN REACTION; SURVIVAL; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW; BONE MARROW CELLS; CYCLOPHOSPHAMIDE; DNA PROBES; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MICE; MICE, SCID; OLIGONUCLEOTIDES, ANTISENSE; PHILADELPHIA CHROMOSOME; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; THIONUCLEOTIDES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0030614494     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.2.124     Document Type: Article

References (29)

1. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res 1991;51:4505-10.
2. Stein CA, Cheng YC. Antisense oligodeoxynucleotides as therapeutic agents - is the bullet really magical? Science 1993;261:1004-12.
3. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature 1996;372:333-5.
4. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 1992;89:11823-7.
5. 1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1994;91:4504-8.
6. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70:901-10.
7. Afar DE, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science 1994;264: 424-6.
8. Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, et al. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 1995;182:1645-53.
9. Skorski T, Nieborowska-Skorska M, Wlodarski P, Zon G, Iozzo RV, Calabretta B. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Blood 1996;88: 1005-12.
10. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78:539-42.
11. Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szczylik C, Chen ST, et al. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 1993;92:194-202.
12. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, et al. Selective inhibition of leukemic cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991;253:562-5.
13. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993;74:609-19.
14. Miyashita T, Reed JC. Tumor suppression p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
15. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents [published erratum appears in Oncogene 1993;8:2605]. Oncogene 1993;8:307-18.
16. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 1995;92:5287-91.
17. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
18. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
19. Feinstein E, Cimino G, Gale RP, Alimena G, Beithier R, Kishi K, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A 1991;88:6293-7.
20. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, et al. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis [published erratum appears in Oncogene 1995; 10:1259]. Oncogene 1994;9:3743-51.
21. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 1991;88:7595-9.
22. Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci U S A 1989;86:6454-8.
23. Iversen PL, Zhu S, Meyer A, Zon G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 1992;2:211-22.
24. Bennett RM. As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells. Antisense Res Dev 1993;3:235-41.
25. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995;95:1814-23.
26. Shirota T, Tavassoli M. Cyclophosphamide-induced alterations of bone marrow endothelium: implications in homing of marrow cells after transplantation. Exp Hematol 1991;19:369-73.
27. Chandra S, Stefani S. Plasma membrane as a sensitive target in radiation-induced cell injury and death: an ultrastructural study. Int J Radiat Biol Relat Stud Phys Chem Med 1981;40:305-11.
28. Yukawa O, Nakazawa T. Radiation-induced lipid peroxidation and membrane-bound enzymes in liver microsomes. Int J Radiat Biol Relat Stud Phys Chem Med 1980;37:621-31.
29. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75: 241-51.